Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00966914 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin
A Phase 3 study, sponsored by BioNumerik Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
NCT00966914: Completed Phase 3 study, sponsored by BioNumerik Pharmaceuticals.
NCT00966914 is a Phase 3 study that has completed, run by BioNumerik Pharmaceuticals. The registered enrollment target is 540 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00966914, a Phase 3 study, has completed, sponsored by BioNumerik Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
Study Summary
Tavocept is an investigational drug that is being developed to see if it can increase the survival of patients who are being treated with chemotherapy as well as to see if it can prevent or reduce side effects of chemotherapy. This research study is aimed at trying to find out if people with advanced adenocarcinoma of the lung who are treated with a standard combination of chemotherapy drugs will live longer if they are also treated with an investigational drug called "Tavocept." Another objective of this research study is to find out whether or not Tavocept helps to prevent or reduce side-effects like kidney damage, anemia, and nausea and vomiting that can occur with these drug combinations. The drug combinations that will be used in this research study will include either paclitaxel and cisplatin, or docetaxel and cisplatin. These drug combinations are approved to be used to treat people with advanced NSCLC. Every patient on this research study will be treated with standard chemotherapy for primary NSCLC in the form of either docetaxel or paclitaxel (these will be recommended by your research study doctor), which will be given in combination with cisplatin.
Interventions
- DRUG Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
- DRUG Placebo in combination with cisplatin and docetaxel or paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
What the finished NCT00966914 record still lists
NCT00966914 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 2 interventions - of which Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel is the first listed.
NCT00966914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00966914 about?
NCT00966914 is a clinical study titled "Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin". Tavocept is an investigational drug that is being developed to see if it can increase the survival of patients who are being treated with chemotherapy as well as to see if it can prevent or reduce side effects of chemotherapy. This research study is aimed at trying to find out if people with advance...
What is the current status of trial NCT00966914?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2010-04. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00966914?
The interventions under investigation include: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel (DRUG), Placebo in combination with cisplatin and docetaxel or paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00966914?
This trial is sponsored by BioNumerik Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00966914's enrollment target sits among peer trials
540 694th of 2000 higher than 1,301 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia